Michael Schenker

Research interests

Publications

• Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

  The Lancet · 2025 · 10.1016/s0140-6736(25)00403-9

• Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

  The Lancet · 2025 · 10.1016/s0140-6736(24)02848-4

• Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274

  Journal of Clinical Oncology · 2024 · 10.1200/jco.24.00340

• Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.

  Journal of Clinical Oncology · 2024 · 10.1200/jco.2024.42.17_suppl.lba4008

• First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial

  Journal of Clinical Oncology · 2024 · 10.1200/jco.23.01601

• Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

  New England Journal of Medicine · 2024 · 10.1056/nejmoa2402141

• First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

  The Lancet Oncology · 2023 · 10.1016/s1470-2045(23)00329-7

• Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma

  New England Journal of Medicine · 2023 · 10.1056/nejmoa2309863

• Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

  Clinical Cancer Research · 2023 · 10.1158/1078-0432.ccr-22-3145

• A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

  Journal of Clinical Oncology · 2022 · 10.1200/jco.22.01003

• First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

  Journal of Thoracic Oncology · 2022 · https://doi.org/10.1016/j.jtho.2022.10.014

• Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

  Journal of Clinical Oncology · 2022 · 10.1200/jco.22.00533

• Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

  Nature · 2022 · 10.1038/s41586-022-04508-4

• Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2032125

• First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00797-2

• First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(20)30641-0

• Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

  Journal of Clinical Oncology · 2021 · 10.1200/jco.20.02212

• Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2034442

• First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

  ESMO Open · 2021 · https://doi.org/10.1016/j.esmoop.2021.100273

• First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

  Journal of Thoracic Oncology · 2021 · 10.1016/j.jtho.2021.09.010

• Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

  The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30494-0

• LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study

  Annals of Oncology · 2020 · 10.1016/j.annonc.2020.08.2296

• Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.

  Journal of Clinical Oncology · 2020 · 10.1200/jco.2020.38.15_suppl.9501

• Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

  European Journal of Cancer · 2019 · 10.1016/j.ejca.2019.05.008

• Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

  Annals of Oncology · 2018 · 10.1093/annonc/mdy264

• Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1709030

Current projects

No projects listed.